MOLECURE
LIVE

Serial Number

97180459

Owner

MOLECURE SPÓLKA AKCYJNA

Attorney

David Orms

Filing Date

Dec 20, 2021

Add to watchlist:

No watchlists yet
View on USPTO

MOLECURE Trademark

Serial Number: 97180459 • Registration: 7599933

MOLECURE is a trademark filed by MOLECURE SPÓLKA AKCYJNA on December 20, 2021. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

MOLECURE SPÓLKA AKCYJNA

UL. ZWIRKI I WIGURY 101
WARSZAWA POLAND 02-089 , PL

Entity Type: 03

OncoArendi Therapeutics S.A.

ul. Zwirki i Wigury 101
Warszawa 02-089 , PL

Entity Type: 99

Trademark Details

Filing Date

December 20, 2021

Registration Date

December 10, 2024

Published for Opposition

May 23, 2023

Goods & Services

Medical and pharmacological research services; research and development services in the field of antibodies; research and development services in the field of immunology; research and development in the pharmaceutical and biotechnology fields; drug discovery services; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; biological research, clinical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer, and medical research; medical laboratory services; scientific laboratory services; analysis of human tissues for medical research; laboratory services, namely, laboratory research services, medical laboratory services, scientific laboratory services relating to the production of monoclonal antibodies; medical research and scientific analysis in the field of immunology and antibodies; scientific research for medical purposes in the area of cancerous diseases; biomedical research services; biological research; research relating to biotechnology; clinical research and medical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemical research and analysis services including analytical services relating to medicines, pharmaceutical preparations and biochemistry; research laboratories, namely, laboratory research in the field of chemistry; scientific and biotechnology research in the field of gene therapy; DNA screening for scientific research purposes; biological research, namely, cell separation research services; research and development services in the field of immunohistology; scientific research in the field of genetics and genetic engineering; consultancy relating to research and development in the field of therapeutics; product custom design and development of medical technology; services for the development of methods of testing, namely, development and establishment of testing specifications and procedures in the field of biotechnology and pharmaceutical fields; conducting technical project studies, namely, technical research in the field of pharmaceutical studies; preparation of project analysis studies, namely, conducting scientific study in the fields of medicine and biotechnology; technical consultancy relating to product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory services relating to scientific research; providing information about the results of clinical trials for others for pharmaceutical products

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 10, 2024 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 14, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Nov 14, 2024 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 14, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 14, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 13, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 10, 2024 GNRT
SU - NON-FINAL ACTION - WRITTEN
Oct 10, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 12, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 12, 2024 CRFA
ASSIGNED TO LIE
Sep 12, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 24, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 24, 2024 GNRT
SU - NON-FINAL ACTION - WRITTEN
Jan 24, 2024 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Jan 24, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 23, 2024 AITU
USE AMENDMENT FILED
Jan 4, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Jan 4, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 18, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 23, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 23, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 3, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 20, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 20, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 20, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 20, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 20, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 28, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 27, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Oct 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Oct 14, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 25, 2022 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 7, 2022 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 27, 2021 NWOS
NEW APPLICATION ENTERED
Dec 23, 2021 NWAP